Business
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February.
About this update from Volitionrx Limited
[{"type":"text","content":"Showing New Indication for Nu.Q® NETs ","length":37,"tagName":"p","attribs":{}},{"type":"text","content":"HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February.","length":285,"tagName":"p"},{"type":"text","content":"The session entitled "Empowering Precision‑medicine approach through NETs Plasma Biomarker‑driven personalized treatment" will be presented by Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece.","length":307,"tagName":"p"},{"type":"text","content":"Professor Evangelos J. Giamarellos-Bourboulis commented:","length":56,"tagName":"p"},{"type":"text","content":""The scientific program at the EHSF conference this year provides a focus on genetics and updates on basic research, including the diagnosis and management of Hidradenitis Suppurativa (HS).","length":199,"tagName":"p"},{"type":"text","content":""I am delighted to present data from the recently released clinical study demonstrating the use of Volition's Nu.Q® NETs assay in patient management for HS, a chronic lifelong disease, which affects approximately 1% of the world's population1.","length":256,"tagName":"p"},{"type":"text","content":""Since the advent of biologicals in the treatment of HS, there has been growing evidence that treatment response varies greatly so that some patients may experience substantial improvement, others no benefit at all and some may even worsen.","length":245,"tagName":"p"},{"type":"text","content":""Those considerations call for a precision medicine approach, which will be the focus of the Symposium. The findings from our study demonstrate that for the first time an easy-to-measure blood test, Nu.Q® NETs, can be used to classify HS patients and help guide treatment selection and modification.","length":304,"tagName":"p"},{"type":"text","content":""In addition, given the various biologic therapies currently in development, we will also explore the potential use of circulating H3.1 nucleosomes as a biomarker for ongoing and future clinical studies.","lengt...